Showing 1341-1350 of 1484 results for "".
- Clearside Biomedical Completes Randomization in Phase 2b Clinical Trial of CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-randomization-in-phase-2b-clinical-trial-of-cls-ax-in-wet-amd/2482013/Clearside Biomedical announced it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in wet age-related macular degeneration (AMD). Topline data results are expected in the third quarter of 2024. “As we continue
- NEI Director Highlights Metabolomics as an Approach to Understanding Glaucomahttps://modernod.com/news/nei-director-highlights-metabolomics-as-an-approach-to-understanding-glaucoma/2481982/The National Eye Institute (NEI) announced that NEI Director Michael F. Chiang, MD, featured recent research by NEI grantee Louis Pasquale, MD, in a National Institute of Health Director’s Blog post. Dr. Pasquale in collaboration with Jae Hee Kang, ScD, and Oana Zeleznik, PhD, explored 369
- Tilak Healthcare Raises €10 Million to Continue Growing Its Ophthalmological Telemedicine Offeringhttps://modernod.com/news/tilak-healthcare-raises-eur10-million-to-continue-growing-its-leading-ophthalmological-telemedicine-offering/2481890/Tilak Healthcare has raised €10 million in a funding to accelerate the roll-out of OdySight in France and abroad, and to develop new solutions for other medical conditions. OdySight is the first remote monitoring system for ophthalmic conditions combined with a gaming interface designed
- Melt Pharmaceuticals Announces Development and License Agreement with Catalent for Its Zydis Fast-Dissolve Technologyhttps://modernod.com/news/melt-pharmaceuticals-announces-development-and-license-agreement-with-catalent-for-its-zydis-fast-dissolve-technology/2481857/Melt Pharmaceuticals, a former subsidiary of Harrow Health, announced it has entered into an exclusive development and license agreement with Catalent in which Melt will utilize Catalent’s proprietary Zydis orally disintegrating tablet (ODT) fast-dissolve technology with MELT
- At-Home App Helps Patients Stay Engaged and Adherent to Vision Monitoring Remotelyhttps://modernod.com/news/at-home-app-helps-patients-stay-engaged-and-adherent-to-vision-monitoring-remotely/2479208/Novartis announced it has begun a US pilot program for OdySight, a clinically tested mobile application designed to help monitor vision remotely. Recent changes to public health protocols, paired with a growing patient population and existing treatment burden, have placed an emphasis on vi
- Regeneron’s Inmazeb Becomes First FDA-Approved Treatment for Ebola Virushttps://modernod.com/news/regenerons-inmazeb-becomes-first-fda-approved-treatment-for-ebola-virus/2478420/The FDA announced Wednesday that it has approved Regeneron Pharmaceuticals’ triple antibody cocktail Inmazeb (atoltivimab/maftivimab/odesivimab-ebgn) for use in adult and paediatric patients, making it the first drug cleared in the US to treat Ebola virus infection. According to the a
- ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-receives-orphan-drug-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2477112/ProQR Therapeutics announced that it received orphan drug designation (ODD) from the FDA for QR-1123, a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H m
- Tilak Healthcare Announces Exclusive Partnership for Co-Promotion with Novartis Francehttps://modernod.com/news/tilak-healthcare-announces-exclusive-partnership-for-co-promotion-with-novartis-france/2476578/Tilak Healthcare, a video game studio specializing in mobile medical games for patients with chronic diseases, announced an exclusive co-promotion partnership with Novartis France for OdySight, its first clinically validated mobile game to monitor vision remotely. Tilak He
- Grant Sealockhttps://modernod.com/profiles/grant-sealock/jQ4n4e/
- Diana Shechtman, OD, FAAOhttps://modernod.com/profiles/diana-shechtman-od-faao/jmQ4xR/Dr. Diana Shechtman is a board-certified optometric physician. She completed her undergraduate studies with honors at University of Florida. She was awarded her Doctor of Optometry degree with honors by Nova Southeastern University College of Optometry. In 1999, she completed a residency focused o…